SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123267
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:25
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eypt-20240930.htm   iXBRL 10-Q 2038161
2 EX-10.1 eypt-ex10_1.htm EX-10.1 185814
3 EX-10.2 eypt-ex10_2.htm EX-10.2 35904
4 EX-31.1 eypt-ex31_1.htm EX-31.1 13735
5 EX-31.2 eypt-ex31_2.htm EX-31.2 14095
6 EX-32.1 eypt-ex32_1.htm EX-32.1 6065
7 EX-32.2 eypt-ex32_2.htm EX-32.2 6156
  Complete submission text file 0000950170-24-123267.txt   8795251

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20240930.xsd EX-101.SCH 1318245
79 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20240930_htm.xml XML 1462051
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51122 | Film No.: 241435506
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)